var data={"title":"Pilocarpine (ophthalmic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pilocarpine (ophthalmic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390320?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pilocarpine-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pilocarpine (ophthalmic): Patient drug information&quot;</a> and <a href=\"topic.htm?path=pilocarpine-ophthalmic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pilocarpine (ophthalmic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505057\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Isopto Carpine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505058\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Diocarpine;</li>\n      <li>Isopto Carpine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9509748\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Ophthalmic Agent, Antiglaucoma;</li>\n      <li>\n        Ophthalmic Agent, Miotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505229\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Elevated intraocular pressure:</b> Ophthalmic: Instill one drop into the affected eye(s) up to 4 times daily; initiate pilocarpine-naive patients on the 1% concentration. <b>Note:</b> Strength of solution and frequency of instillation dependent on degree of pressure elevation and patient miotic response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glaucoma (acute angle closure):</b> Ophthalmic: Initial: Instill 1 drop of 1% or 2% solution into the affected eye(s) up to 3 times over a 30-minute period; pretreatment with secretory suppressant and hyperosmotic agent may be required to lower pressure below 50 mm Hg and relieve iris ischemia. If laser iridoplasty or iridomy is used to break the attack, instill 1 drop of 4% solution prior to the procedure; following laser iridoplasty, instill 1 drop of 1% solution 4 times daily until an iridotomy can be performed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Miosis:</b> Ophthalmic: Instill 1 drop (or 2 drops 5 minutes apart) into the affected eye(s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of postoperative elevated IOP:</b> Ophthalmic: Instill 1 drop (or 2 drops 5 minutes apart) into the affected eye(s) 15 to 60 minutes prior to surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>To counteract the mydriatic effects of sympathomimetic agents (off-label use):</b> Ophthalmic: Solution: Instill 1 drop of a 1% solution in the affected eye.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46361386\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pilocarpine-ophthalmic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pilocarpine (ophthalmic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Elevated intraocular pressure:</b> Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: Instill 1 drop of the 1% solution into the affected eye(s) 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glaucoma (acute angle closure):</b> Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: Instill 1 drop of the 1% solution into the affected eye(s) 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Miosis:</b> Ophthalmic: Infants, Children, and Adolescents: For induction of miosis prior to goniotomy or trabeculectomy, instill 1 drop of 1% or 2% solution into the eye(s) 15 to 60 minutes prior to surgery</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505230\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370238\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370239\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505257\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isopto Carpine: 1% (15 mL); 2% (15 mL); 4% (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1% (15 mL); 2% (15 mL); 4% (15 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505060\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505233\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Gently apply finger pressure to the lacrimal sac for 2 minutes following administration. Remove contact lenses prior to instillation and wait 10 to 15 minutes before reinserting. Separate administration of other ophthalmic agents by at least 5 minutes. Do not touch the tip of the dropper to the eye, fingertips, or other surface.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505061\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Elevated intraocular pressure: </b>Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glaucoma: </b>Management of acute angle-closure glaucoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Miosis:</b> Induction of miosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of postoperative elevated IOP:</b> Prevention of postoperative elevated IOP associated with laser surgery</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744668\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Counter effects of cycloplegics</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505047\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Isopto Carpine may be confused with Isopto Carbachol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505079\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Hypertension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, salivation, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ocular: Burning, ciliary spasm, conjunctival vascular congestion, corneal granularity (gel 10%), lacrimation, lens opacity, myopia, retinal detachment, supraorbital or temporal headache, visual acuity decreased</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchial spasm, pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Diaphoresis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505071\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to pilocarpine or any component of the formulation; conditions where pupillary constriction is undesirable (eg, acute iritis, anterior uveitis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505072\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: Use caution when driving at night and other hazardous occupations in poor illumination; may cause decreased visual acuity, especially at night or with reduced lighting. In addition, miotics may also cause accommodative spasm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Use with caution in patients with asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with acute heart failure, recent myocardial infarction (MI), hypertension and/or hypotension. In a scientific statement from the American Heart Association, ophthalmic cholinergic agents have been determined to be agents that may exacerbate underlying myocardial dysfunction (magnitude: minor) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI disease: Use with caution in patients with peptic ulcer disease or GI spasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular inflammation: Use is not recommended when iritis is present. Avoid miotics in acute inflammatory diseases of the anterior chamber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Retinal disease: Rare cases of retinal detachment have been reported; use with caution in susceptible patients and those with preexisting retinal disease; a thorough examination of retina (including funduscopy) is recommended prior to initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary tract obstruction: Use with caution in patients with urinary tract obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in pediatric patients with primary congenital glaucoma for control of IOP; cases of paradoxical increase in IOP have been reported. Use is not recommended in pediatric patients diagnosed with glaucoma secondary to anterior segment dysgenesis or uveitis (especially if uveitis is active).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: May contains benzalkonium chloride which may be adsorbed and cause discoloration of soft contact lenses; remove contacts prior to administration and wait 10 to 15 minutes before reinserting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505084\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2A6 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505087\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9903&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclopentolate: May diminish the therapeutic effect of Pilocarpine (Ophthalmic).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505069\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9887312\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617930\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pilocarpine (ophthalmic) is excreted in breast milk. The manufacturer recommends that caution be exercised when administering pilocarpine (ophthalmic) to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505236\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intraocular pressure, funduscopic exam (before therapy initiation), visual field testing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505100\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Directly stimulates cholinergic receptors in the eye causing miosis (by contraction of the iris sphincter), loss of accommodation (by constriction of ciliary muscle), and lowering of intraocular pressure (with decreased resistance to aqueous humor outflow)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505104\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Miosis: 10 to 30 minutes; Intraocular pressure reduction: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Miosis: 4 to 8 hours; Intraocular pressure reduction: 4 to 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9505259\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isopto Carpine Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (15 mL): $111.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (15 mL): $114.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (15 mL): $119.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pilocarpine HCl Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (15 mL): $94.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2% (15 mL): $96.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (15 mL): $101.61</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962002\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apicarpine (JO, QA);</li>\n      <li>Asthenopin (PH);</li>\n      <li>Carpine (BD);</li>\n      <li>Isopto Carpina (AR, CO, ES, PE, PY, UY, VE);</li>\n      <li>Isopto Carpine (AE, AU, BB, BE, BF, BH, BJ, CI, CY, EE, EG, ET, FI, GH, GM, GN, GR, HK, HN, IE, IQ, IR, IS, JO, KE, KW, LB, LK, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PH, PL, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZM, ZW);</li>\n      <li>Isopto Pilocarpina (CL);</li>\n      <li>Isopto Pilocarpine (FR);</li>\n      <li>Isopto-Carpine (VN);</li>\n      <li>Liocarpina (IT);</li>\n      <li>Locarp (IN);</li>\n      <li>Medicarpine (PK);</li>\n      <li>Miokar (ID);</li>\n      <li>O.P.D. (TW);</li>\n      <li>Ocu-Carpine (KR);</li>\n      <li>Ocusert Pilo-20 (GB);</li>\n      <li>Ocusert Pilo-40 (GB);</li>\n      <li>Ocusert Pilocarpine (GB);</li>\n      <li>Oftan-Pilocarpin (FI);</li>\n      <li>P.V. Carpine Liquifilm Ophthalimic Solution (AU, NZ);</li>\n      <li>Pil Ofteno (GT, SV);</li>\n      <li>Pilo (BE, FR);</li>\n      <li>Pilocan (BR);</li>\n      <li>Pilocar (VE);</li>\n      <li>Pilocarpol (DE);</li>\n      <li>Pilogel (GB, IE, TW);</li>\n      <li>Pilogel HS (CL, CZ, SG, SI);</li>\n      <li>Pilokarpin (DK, SI, SK);</li>\n      <li>Pilomann (DE);</li>\n      <li>Pilomin (BD, BG);</li>\n      <li>Pilopes (BD);</li>\n      <li>Pilopine-HS (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Pilopos (CZ);</li>\n      <li>Pilopt Eye Drops (AU, NZ);</li>\n      <li>Pilotina (QA);</li>\n      <li>Pilotonina (IT);</li>\n      <li>Sno Pilo (AE, IE);</li>\n      <li>Spersacarpin (DE);</li>\n      <li>Spersacarpine (CH, MY, PK, SE, TW);</li>\n      <li>Zhenrui (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Isopto Carpine (pilocarpine hydrochloride) [prescribing information]. Fort Worth, TX: Alcon Laboratories; June 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isopto Carpine (pilocarpine hydrochloride) [product monograph]. Mississauga, Ontario, Canada: Alcon Canada Inc; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pilocarpine-ophthalmic-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9903 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9505057\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9505058\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9509748\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9505229\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46361386\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9505230\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22370238\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22370239\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9505257\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9505060\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9505233\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9505061\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744668\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9505047\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9505079\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9505071\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9505072\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9505084\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9505087\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9505069\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9887312\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617930\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9505236\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9505100\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9505104\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9505259\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962002\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9903|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pilocarpine-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">Pilocarpine (ophthalmic): Patient drug information</a></li><li><a href=\"topic.htm?path=pilocarpine-ophthalmic-pediatric-drug-information\" class=\"drug drug_pediatric\">Pilocarpine (ophthalmic): Pediatric drug information</a></li></ul></div></div>","javascript":null}